Asbell Penny A, Potapova Natalia
Department of Ophthalmology, Mount Sinai Medical Center, New York, New York 10029, USA.
Ocul Surf. 2005 Jan;3(1):27-40. doi: 10.1016/s1542-0124(12)70120-9.
The side effects of topical antiglaucoma medications and their preservatives range from ocular discomfort to sight-threatening alterations of the ocular surface. Conjunctival hyperemia, decreased tear production and function, and superficial punctate keratitis are among the most common signs seen on routine clinical examination. Squamous cell metaplasia and changes in cell morphology have been demonstrated by impression cytology studies and evaluation of biopsy specimens, and inflammatory effects are documented by the presence of inflammatory markers. The adverse effects of topical antiglaucoma eyedrops interfere with the treatment of glaucoma on two levels: first, the discomfort produced by the eye drops discourages patient compliance; and, second, long-term treatment with eyedrops is associated with a higher failure of filtration surgery. The detailed mechanism of inflammatory response and/or direct toxicity of eye drops has yet to be determined, but it may vary with the different classes of eye drops, different preservatives, and durations of treatments. Upcoming multicenter trials for new antiglaucoma eye drops should specifically evaluate ocular surface effects.
局部抗青光眼药物及其防腐剂的副作用范围从眼部不适到威胁视力的眼表改变。结膜充血、泪液分泌和功能减少以及浅层点状角膜炎是常规临床检查中最常见的体征。印象细胞学研究和活检标本评估已证实鳞状上皮化生和细胞形态变化,炎症标志物的存在记录了炎症效应。局部抗青光眼滴眼液的不良反应在两个层面上干扰青光眼的治疗:第一,滴眼液产生的不适会降低患者的依从性;第二,长期使用滴眼液与滤过性手术失败率较高有关。滴眼液炎症反应和/或直接毒性的详细机制尚未确定,但可能因滴眼液的不同类别、不同防腐剂和治疗持续时间而异。即将开展的新型抗青光眼滴眼液多中心试验应专门评估眼表效应。